Jazz Pharmaceuticals plc
JAZZNASDAQHealthcare● Active
$233.59
$-4.98(-2.09%)
Market Cap$14.7B
P/E Ratio—
52W High$243.32
52W Low$105
Jazz Pharmaceuticals plc (JAZZ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
JAZZ · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$6.34
Est. $4.64 · +36.6%
Revenue
$1.07B
Est. $0.98B · +9.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
JAZZ reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $6.18 | — | — | — | $1.11B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $4.64 | $6.34 | +36.6% | $1.07B | $0.98B | +9.2% |
| ▲ Q1 FY2026 | Feb 24, 2026 | $6.52 | $6.64 | +1.8% | $1.20B | $1.17B | +2.8% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $5.95 | $8.13 | +36.6% | $1.13B | $1.11B | +1.4% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$6.12 | -$8.25 | -34.8% | $1.05B | $1.05B | -0.1% |
| ▼ Q2 FY2025 | May 6, 2025 | $4.51 | $1.68 | -62.8% | $0.90B | $1.06B | -15.7% |
| ▲ Q1 FY2025 | Feb 25, 2025 | $5.83 | $6.60 | +13.2% | $1.09B | $0.98B | +10.5% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $5.47 | $6.61 | +20.8% | $1.05B | $1.06B | -0.2% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$6.18
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$6.34
EPS Est.
$4.64
EPS Surpr.
+36.6%
Revenue
$1.07B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$6.64
EPS Est.
$6.52
EPS Surpr.
+1.8%
Revenue
$1.20B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$8.13
EPS Est.
$5.95
EPS Surpr.
+36.6%
Revenue
$1.13B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$8.25
EPS Est.
-$6.12
EPS Surpr.
-34.8%
Revenue
$1.05B
Q2 FY2025
May 6, 2025Miss
EPS Actual
$1.68
EPS Est.
$4.51
EPS Surpr.
-62.8%
Revenue
$0.90B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
$6.60
EPS Est.
$5.83
EPS Surpr.
+13.2%
Revenue
$1.09B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$6.61
EPS Est.
$5.47
EPS Surpr.
+20.8%
Revenue
$1.05B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $6.80 | $7.07 | $7.35 | 4 |
| Q3 FY2027 | $6.59 | $6.85 | $7.12 | 8 |
| Q2 FY2027 | $6.02 | $6.26 | $6.51 | 5 |
| Q1 FY2027 | $5.43 | $5.65 | $5.87 | 4 |
| Q4 FY2026 | $6.07 | $6.32 | $6.56 | 4 |
| Q3 FY2026 | $6.04 | $6.36 | $6.59 | 11 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.3B | $1.3B | $1.4B | 5 |
| Q3 FY2027 | $1.2B | $1.3B | $1.3B | 9 |
| Q2 FY2027 | $1.1B | $1.2B | $1.2B | 6 |
| Q1 FY2027 | $1.1B | $1.1B | $1.1B | 5 |
| Q4 FY2026 | $1.1B | $1.2B | $1.2B | 5 |
| Q3 FY2026 | $1.1B | $1.2B | $1.2B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +36.6% | $208.06 | $212.26 | +2.02% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +1.8% | $173.25 | $173.83 | +0.33% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +36.6% | $137.82 | $137.22 | -0.44% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -34.8% | $116.10 | $113.20 | -2.50% |
| ▼ Q2 FY2025 | May 6, 2025 | -62.8% | $118.19 | $111.17 | -5.94% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +13.2% | $136.69 | $139.67 | +2.18% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +20.8% | $111.43 | $111.55 | +0.11% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +13.3% | $112.27 | $110.25 | -1.80% |
Q2 FY2026+2.02%
Report Date
May 5, 2026
EPS Beat/Miss
+36.6%
Price Before
$208.06
Price After
$212.26
Q1 FY2026+0.33%
Report Date
Feb 24, 2026
EPS Beat/Miss
+1.8%
Price Before
$173.25
Price After
$173.83
Q4 FY2025-0.44%
Report Date
Nov 5, 2025
EPS Beat/Miss
+36.6%
Price Before
$137.82
Price After
$137.22
Q3 FY2025-2.50%
Report Date
Aug 5, 2025
EPS Beat/Miss
-34.8%
Price Before
$116.10
Price After
$113.20
Q2 FY2025-5.94%
Report Date
May 6, 2025
EPS Beat/Miss
-62.8%
Price Before
$118.19
Price After
$111.17
Q1 FY2025+2.18%
Report Date
Feb 25, 2025
EPS Beat/Miss
+13.2%
Price Before
$136.69
Price After
$139.67
Q4 FY2024+0.11%
Report Date
Nov 6, 2024
EPS Beat/Miss
+20.8%
Price Before
$111.43
Price After
$111.55
Q3 FY2024-1.80%
Report Date
Jul 31, 2024
EPS Beat/Miss
+13.3%
Price Before
$112.27
Price After
$110.25
Avg Beat Reaction+0.40%
Avg Miss Reaction-4.22%
Beat Rate6 / 8 quarters
Largest Move-5.94% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: JAZZ ends December
Jazz Pharmaceuticals plc (JAZZ) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $6.34 — beating the analyst consensus of $4.64 by +36.6%. JAZZ has beaten EPS estimates for 3 consecutive quarters. The next JAZZ earnings date is expected around September 1, 2026.
Each quarter, investors track JAZZ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. JAZZ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
JAZZ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
JAZZ earnings · 5 questionsJazz Pharmaceuticals plc's next earnings report is expected around September 1, 2026. JAZZ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; JAZZ historically reports after market close (AMC).
JAZZ earnings datewhen is JAZZ earningsJAZZ next earnings datewhen does JAZZ report earningsJAZZ earnings calendar
▸ Source: FMP · Jazz Pharmaceuticals plc SEC filings · US GAAP · Jazz Pharmaceuticals plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026